



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

7 4 7 1 '03 JUL 21 4 00 PM
Re: Evoxac
Docket No. 01E-0405

The Honorable James. E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Rogan:

This is in regard to the patent term extension application for U.S. Patent No. 4,855,290 filed by State of Israel, Israel Institute for Biological Research under 35 U.S.C. § 156. The patent claims Evoxac (cevimeline HCl), NDA 20-989.

In the November 18, 2002, issue of the Federal Register (67 Fed. Reg. 69533), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before May 19, 2003, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Jane A. Axelrad

Associate Director for Policy
Center for Drug Evaluation and Research

cc: Paul E. White
Pillsbury, Madison & Sutro, L.L.P.
Intellectual Property Group
1600 Tysons Blvd
McLean, VA 22102

01E-0405

LET S